Sandoz: The Share Price May Have Run Its Course
Sandoz delivered steady revenue and EBITDA growth, with 2025 revenue projected near $11B and EBITDA margin guidance raised to 21-22%. SDZNY now trades at a relatively rich EV/EBITDA multiple of ~16 for 2025 and ~13 forward based on 2027 consensus estimates. While the business model and growth profile remain attractive, current valuation justifies only a "hold" rating after a 65% share price run-up.
Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why
Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wednesday.
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q2 2025 Earnings Conference Call August 7, 2025 3:00 AM ET Company Participants Craig Marks - Corporate Participant Head, IR - Corporate Participant Remco J. Steenbergen - Chief Financial Officer Richard Saynor - Chief Executive Officer Conference Call Participants Charlie Haywood - BofA Securities, Research Division Florent Cespedes - Sanford C.
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard Saynor told the Financial Times.
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
